QTTB

SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 5

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,880 shares

Expires 2031-01-21

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 4

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,238

Underlying: Common Stock · 6,238 shares

Expires 2028-12-06

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 3

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,238 shares

Expires 2028-12-06

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 2

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,013

Underlying: Common Stock · 2,013 shares

Expires 2028-12-06

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 1

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,013 shares

Expires 2028-12-06

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 6

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 5

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 4

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,947

Underlying: Common Stock · 1,947 shares

Expires 2031-12-16

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 3

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,947 shares

Expires 2031-12-16

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 2

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,431

Underlying: Common Stock · 5,431 shares

Expires 2031-09-16

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 1

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,431 shares

Expires 2031-09-16

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 7

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,008

Underlying: Common Stock · 19,008 shares

Expires 2035-01-14

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 6

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,008 shares

Expires 2035-01-14

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 4

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,627

Underlying: Common Stock · 2,627 shares

Expires 2034-03-31

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 3

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,627 shares

Expires 2034-03-31

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 2

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 5

Kalowski Lee · CIK 0001618273 · CFO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,323

Underlying: Common Stock · 161,323 shares

Expires 2033-10-12

F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 4

Kalowski Lee · CIK 0001618273 · CFO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 161,323 shares

Expires 2033-10-12

F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 3

Kalowski Lee · CIK 0001618273 · CFO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,901

Underlying: Common Stock · 16,901 shares

Expires 2033-11-08

F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 2

Kalowski Lee · CIK 0001618273 · CFO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,901 shares

Expires 2033-11-08

F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028269 · ownership.xml · nonDerivative · entry 1

Kalowski Lee · CIK 0001618273 · CFO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,250

F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.

SEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 4

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 3

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 2

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,674

Underlying: Common Stock · 25,674 shares

Expires 2026-04-22

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 1

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,674 shares

Expires 2026-04-22

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028249 · ownership.xml · derivative · entry 5

GRAYZEL DAVID S. · CIK 0001732786 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,595

Underlying: Common Stock · 18,595 shares

Expires 2035-01-14

F5 · kind: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued board service through such date.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued board service through such date.

F3 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 10

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,140

Underlying: Common Stock · 23,140 shares

Expires 2035-01-14

F4 · kind: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported.

SEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 5

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,008

Underlying: Common Stock · 19,008 shares

Expires 2035-01-14

F4 · kind: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported.

F4 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported.

SEC source: 0000950170-24-115146 · ownership.xml · derivative · entry 6

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,891

Underlying: Common Stock · 6,000 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in sixteen (16) equal quarterly installments following December 2, 2020, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-115146 · ownership.xml · nonDerivative · entry 2

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,874

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-115146 · ownership.xml · derivative · entry 5

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,361 shares

Expires 2028-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-115146 · ownership.xml · derivative · entry 4

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 213 shares

Expires 2028-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-115146 · ownership.xml · nonDerivative · entry 1

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,874

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-114051 · ownership.xml · derivative · entry 3

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213

Underlying: Common Stock · 13,300 shares

Expires 2028-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-114051 · ownership.xml · nonDerivative · entry 1

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-110150 · ownership.xml · derivative · entry 1

Lundberg Sven Ante · CIK 0001682126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,316

Underlying: Common Stock · 1,316 shares

Expires 2034-09-24

F1 · derivative.exercise_date: The shares underlying this option vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024.

SEC source: 0000950170-24-096989 · ownership.xml · derivative · entry 1

GRAYZEL DAVID S. · CIK 0001732786 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,569

Underlying: Common Stock · 2,569 shares

Expires 2034-03-31

F1 · kind: This option was granted in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive equity in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · derivative.exercise_date: The shares underlying this option shall vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024.

F3 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000950170-24-110152 · ownership.xml · derivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,627

Underlying: Common Stock · 2,627 shares

Expires 2034-03-31

F1 · kind: This option was granted in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive equity in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · derivative.exercise_date: The shares underlying this option vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024.

SEC source: 0000950170-24-037387 · ownership.xml · derivative · entry 1

LAPORTE KATHLEEN · CIK 0001196201 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037389 · ownership.xml · derivative · entry 1

Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,413

Underlying: Common Stock · 56,413 shares

Expires 2034-03-24

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037403 · ownership.xml · derivative · entry 1

Manke Isaac · CIK 0001622769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037383 · ownership.xml · derivative · entry 1

Kalowski Lee · CIK 0001618273 · CFO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,323

Underlying: Common Stock · 161,323 shares

Expires 2033-10-12

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 13, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037390 · ownership.xml · derivative · entry 1

Morrison Jodie Pope · CIK 0001618247 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 394,445

Underlying: Common Stock · 394,445 shares

Expires 2034-03-24

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037399 · ownership.xml · derivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,534

Underlying: Common Stock · 25,534 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037382 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037404 · ownership.xml · derivative · entry 1

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037392 · ownership.xml · derivative · entry 1

Campagna Jason · CIK 0001793338 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,687

Underlying: Common Stock · 70,687 shares

Expires 2034-03-24

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-24-037397 · ownership.xml · derivative · entry 1

GRAYZEL DAVID S. · CIK 0001732786 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000950170-24-037395 · ownership.xml · derivative · entry 1

Xu Diyong · CIK 0001995088 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.